SK287602B6 - Farmaceutická kompozícia obsahujúca inhibítor lipázy a sacharózomonoester mastnej kyseliny, spôsob jej prípravy a použitie na liečenie obezity - Google Patents

Farmaceutická kompozícia obsahujúca inhibítor lipázy a sacharózomonoester mastnej kyseliny, spôsob jej prípravy a použitie na liečenie obezity Download PDF

Info

Publication number
SK287602B6
SK287602B6 SK1609-2003A SK16092003A SK287602B6 SK 287602 B6 SK287602 B6 SK 287602B6 SK 16092003 A SK16092003 A SK 16092003A SK 287602 B6 SK287602 B6 SK 287602B6
Authority
SK
Slovakia
Prior art keywords
sucrose
fatty acid
composition
orlistat
composition according
Prior art date
Application number
SK1609-2003A
Other languages
English (en)
Slovak (sk)
Other versions
SK16092003A3 (sk
Inventor
Karsten Maeder
Rainer Eugen Martin
Susanne Raab
Lukas Christoph Scheibler
Thomas Schindler
Marco Schroeder
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8177654&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK287602(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of SK16092003A3 publication Critical patent/SK16092003A3/sk
Publication of SK287602B6 publication Critical patent/SK287602B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK1609-2003A 2001-06-06 2002-05-29 Farmaceutická kompozícia obsahujúca inhibítor lipázy a sacharózomonoester mastnej kyseliny, spôsob jej prípravy a použitie na liečenie obezity SK287602B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01113793 2001-06-06
PCT/EP2002/005889 WO2002098412A1 (en) 2001-06-06 2002-05-29 Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester

Publications (2)

Publication Number Publication Date
SK16092003A3 SK16092003A3 (sk) 2004-05-04
SK287602B6 true SK287602B6 (sk) 2011-03-04

Family

ID=8177654

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1609-2003A SK287602B6 (sk) 2001-06-06 2002-05-29 Farmaceutická kompozícia obsahujúca inhibítor lipázy a sacharózomonoester mastnej kyseliny, spôsob jej prípravy a použitie na liečenie obezity

Country Status (40)

Country Link
US (4) US20030027786A1 (ko)
EP (1) EP1399152B1 (ko)
JP (2) JP4261337B2 (ko)
KR (1) KR100753729B1 (ko)
CN (1) CN1514725B (ko)
AR (1) AR034355A1 (ko)
AT (1) ATE356622T1 (ko)
AU (1) AU2002257817B2 (ko)
BG (1) BG66346B1 (ko)
BR (1) BRPI0210266B1 (ko)
CA (1) CA2448030C (ko)
CO (1) CO5540293A2 (ko)
CY (1) CY1107641T1 (ko)
CZ (1) CZ299948B6 (ko)
DE (1) DE60218845T2 (ko)
DK (1) DK1399152T3 (ko)
EC (1) ECSP034871A (ko)
ES (1) ES2282415T3 (ko)
GT (1) GT200200106A (ko)
HK (1) HK1067312A1 (ko)
HR (1) HRP20030983B1 (ko)
HU (1) HU230405B1 (ko)
IL (2) IL158908A0 (ko)
JO (1) JO2455B1 (ko)
MA (1) MA27031A1 (ko)
ME (1) ME00579B (ko)
MX (1) MXPA03011191A (ko)
MY (1) MY161871A (ko)
NO (1) NO328006B1 (ko)
NZ (1) NZ529630A (ko)
PA (1) PA8546701A1 (ko)
PE (1) PE20030230A1 (ko)
PL (1) PL215266B1 (ko)
PT (1) PT1399152E (ko)
RS (1) RS50713B (ko)
RU (1) RU2271808C2 (ko)
SI (1) SI1399152T1 (ko)
SK (1) SK287602B6 (ko)
WO (1) WO2002098412A1 (ko)
ZA (1) ZA200309007B (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US8372430B2 (en) * 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
FI20045076A (fi) * 2004-03-15 2005-09-16 Bioferme Oy Funktionaalinen elintarvike
KR100910000B1 (ko) * 2005-05-13 2009-07-29 씨제이제일제당 (주) 리파아제 저해제 함유 약학 조성물
JP5044398B2 (ja) * 2005-06-09 2012-10-10 武田薬品工業株式会社 固形製剤
US20070111914A1 (en) * 2005-11-16 2007-05-17 Conopco, Inc., D/B/A Unilever, A Corporation Of New York Environmentally friendly laundry method and kit
KR101252635B1 (ko) * 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
EP1872777A1 (en) * 2006-06-27 2008-01-02 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising tetrahydrolipstatin
GB0618725D0 (en) * 2006-09-23 2006-11-01 Jagotec Ag Composition containing inhibitors of gastro-intestinal lipase
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
US8309107B2 (en) * 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
FR2994386B1 (fr) * 2012-08-07 2016-06-24 Thorel Jean-Noel Inhibition de l'adhesion de micro-organismes pathogenes par un ester de saccharose et/ou de sorbitan dans le traitement cosmetique de l'atopie cutanee
US10743813B2 (en) 2014-09-11 2020-08-18 Rattan Nath Diabetes control using postprandial feedback
CN104546768B (zh) * 2014-12-30 2017-06-16 重庆植恩药业有限公司 含有脂肪酶抑制剂的咀嚼片组合物及其制备方法
CA3002924A1 (en) 2015-10-23 2017-04-27 Erx Pharmaceuticals Inc. Analogs of celastrol
CN113151373B (zh) * 2021-03-09 2023-07-04 武汉臻治生物科技有限公司 一种具有抗菌及抗肿瘤活性的蔗糖单酯的制备方法及其应用
KR102637596B1 (ko) 2022-03-18 2024-02-19 (주)보노보씨 기능성 목공교구

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1965133A1 (de) 1969-12-27 1971-07-22 Merck Patent Gmbh Verfahren zur Herstellung pharmazeutischer Zubereitungen
US4148874A (en) * 1977-06-13 1979-04-10 The Procter & Gamble Company Dermatological compositions
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
NL8600050A (nl) 1986-01-13 1987-08-03 Sanico Nv Farmaceutisch preparaat met vertraagde afgifte van het werkzame bestanddeel en werkwijze voor de bereiding er van.
ATE91592T1 (de) * 1986-12-19 1993-08-15 Procter & Gamble Naehrzusammenstellung mit hoeherem blutcholesterol herabsetzenden eigenschaften.
JP2748597B2 (ja) 1989-09-28 1998-05-06 三菱化学株式会社 食品劣化抑制剤
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
JP3112473B2 (ja) 1990-10-18 2000-11-27 オリンパス光学工業株式会社 屈折率分布型光学素子の製造方法
US5294451A (en) * 1991-03-29 1994-03-15 Curtice-Burns, Inc. Fat substitute compositions having reduced laxative effects
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
FR2735658B1 (fr) * 1995-06-21 1997-09-12 Capsulis Encapsulation de composes a usage alimentaire par des tensioactifs
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
EP1105122B1 (en) * 1998-08-14 2005-04-27 F.Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors
TR200100472T2 (tr) 1998-08-14 2001-07-23 F.Hoffmann-La Roche Ag Lipaz inhibitörleri ile sitozan içeren farmasötik bileşimler
WO2000025598A1 (en) 1998-11-03 2000-05-11 Dandy A/S Sucrose fatty acid esters for use as increased release of active ingredients
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
US6348492B1 (en) 1999-10-29 2002-02-19 2Pro Chemical Oxetanone derivatives
IL144045A0 (en) 1999-10-29 2002-04-21 Mullins John Jason Gentry Oxetanone derivatives
HU229550B1 (en) * 2000-06-27 2014-01-28 Hoffmann La Roche Method for preparing compositions
DK1307263T3 (da) 2000-07-28 2005-08-22 Hoffmann La Roche Hidtil ukendt anvendelse af lipaseinhibitorer
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6534097B1 (en) * 2002-07-11 2003-03-18 Betty Baggott Pest repellent

Also Published As

Publication number Publication date
US20110301231A1 (en) 2011-12-08
HUP0401208A2 (hu) 2004-11-29
MA27031A1 (fr) 2004-12-20
PA8546701A1 (es) 2003-01-24
EP1399152B1 (en) 2007-03-14
AU2002257817B2 (en) 2005-08-18
DE60218845T2 (de) 2008-01-03
PE20030230A1 (es) 2003-03-17
HRP20030983A2 (en) 2005-08-31
PL215266B1 (pl) 2013-11-29
CA2448030C (en) 2009-11-24
MY161871A (en) 2017-05-15
US20050101562A1 (en) 2005-05-12
SI1399152T1 (sl) 2007-08-31
NZ529630A (en) 2006-05-26
RU2271808C2 (ru) 2006-03-20
CY1107641T1 (el) 2013-04-18
ME00579A (en) 2011-12-20
ZA200309007B (en) 2005-04-26
BR0210266A (pt) 2004-07-20
MXPA03011191A (es) 2004-02-26
ES2282415T3 (es) 2007-10-16
AR034355A1 (es) 2004-02-18
SK16092003A3 (sk) 2004-05-04
PT1399152E (pt) 2007-06-05
JP2009108076A (ja) 2009-05-21
EP1399152A1 (en) 2004-03-24
HK1067312A1 (en) 2005-04-08
ECSP034871A (es) 2004-01-28
CZ299948B6 (cs) 2009-01-07
JP2004532271A (ja) 2004-10-21
WO2002098412A1 (en) 2002-12-12
KR20040010689A (ko) 2004-01-31
JP4261337B2 (ja) 2009-04-30
CO5540293A2 (es) 2005-07-29
KR100753729B1 (ko) 2007-08-30
CZ20033525A3 (cs) 2004-04-14
NO20035318D0 (no) 2003-11-28
CN1514725B (zh) 2010-04-21
RS96003A (en) 2006-10-27
IL158908A (en) 2008-08-07
GT200200106A (es) 2003-02-11
US8039508B2 (en) 2011-10-18
ATE356622T1 (de) 2007-04-15
DE60218845D1 (de) 2007-04-26
DK1399152T3 (da) 2007-06-18
US8343543B2 (en) 2013-01-01
HU230405B1 (hu) 2016-04-28
IL158908A0 (en) 2004-05-12
BG108421A (en) 2005-02-28
NO328006B1 (no) 2009-11-09
JO2455B1 (en) 2008-10-09
RU2003136728A (ru) 2005-05-20
RS50713B (sr) 2010-06-30
PL366890A1 (en) 2005-02-07
CA2448030A1 (en) 2002-12-12
CN1514725A (zh) 2004-07-21
BG66346B1 (bg) 2013-08-30
HUP0401208A3 (en) 2008-04-28
US20130079391A1 (en) 2013-03-28
US20030027786A1 (en) 2003-02-06
ME00579B (me) 2011-12-20
BRPI0210266B1 (pt) 2016-01-26
HRP20030983B1 (en) 2011-10-31

Similar Documents

Publication Publication Date Title
US8343543B2 (en) Lipase inhibiting composition
US6703369B1 (en) Lipase inhibiting compositions
MXPA02002034A (es) Formulaciones de dispersion que contienen inhibidores de lipasa.
AU2002257817A1 (en) Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester
UA122710C2 (uk) Фармацевтична композиція для попередження аліментарного ожиріння
KR100625399B1 (ko) 리파아제 억제제 및 글루코마난을 포함하는 약학 조성물
TWI336252B (en) Pharmaceutical composition for the treatment and prevention of obesity

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20190529